SCHEMBL432628

SCHEMBL432628

Nc1ccn([C@@H]2O[C@H](COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(O)ncnc54)O[C@@H]3COP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)n1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RNASEL Q05823 13/20 0.67
DNPH1 O43598 1/20 0.61
PRKAB2 O43741 1/20 0.61
TRPM2 O94759 1/20 0.61
LDHA P00338 1/20 0.61
ADRB2 P07550 1/20 0.61
FBP1 P09467 1/20 0.61
SRC P12931 1/20 0.61
ADORA1 P30542 1/20 0.61
P2RY2 P41231 1/20 0.61
P2RY1 P47900 1/20 0.61
PRKAG1 P54619 1/20 0.61
PRKAA2 P54646 1/20 0.61
PDE4D Q08499 1/20 0.61
KCNH2 Q12809 1/20 0.61
PRKAA1 Q13131 1/20 0.61
PDE3A Q14432 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
TAS1R3 Q7RTX0 1/20 0.61
TAS1R1 Q7RTX1 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7677945 0.94 RNASEL (0.76) RNASELDNPH1PRKAB2TRPM2LDHA
SCHEMBL10778019 0.94 RNASEL (0.66) RNASELTRPM2SRCP2RY2P2RY1
SCHEMBL28263983 0.92 P2RY1 (0.63) RNASELDNPH1PRKAB2TRPM2LDHA
Cystetine Triphosphate SCHEMBL10778035 0.90 P2RY1 (0.65) RNASELTRPM2SRCP2RY2P2RY1
SCHEMBL1940955 0.89 RNASEL (0.76) RNASELDNPH1PRKAB2TRPM2LDHA
SCHEMBL4970108 0.89 RNASEL (0.84) RNASELDNPH1PRKAB2TRPM2LDHA
SCHEMBL29452474 0.88 P2RX3 (0.65) RNASELDNPH1PRKAB2TRPM2LDHA
Adenosine Phosphate SCHEMBL28920925 0.88 P2RY1 (0.80) RNASELDNPH1PRKAB2TRPM2LDHA
Adenosine Phosphate SCHEMBL29390023 0.88 P2RY1 (0.80) RNASELDNPH1PRKAB2TRPM2LDHA
SCHEMBL29350567 0.88 P2RY2 (0.65) RNASELP2RY2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3705493-A1 EGFR-HOMING DOUBLE-STRANDED RNA VECTOR FOR SYSTEMIC CANCER TREATMENT TargImmune Therapeutics AG (CH) 2020-09-09 EP disclosed
EP-3098239-B1 EGFR-HOMING DOUBLE-STRANDED RNA VECTOR FOR SYSTEMIC CANCER TREATMENT TARGIMMUNE THERAPEUTICS AG (CH) 2019-10-23 EP disclosed
EP-3098239-A1 EGFR-HOMING DOUBLE-STRANDED RNA VECTOR FOR SYSTEMIC CANCER TREATMENT Levitzki, Alexander (IL) 2016-11-30 EP disclosed
EP-2379597-B1 EGFR-HOMING DOUBLE-STRANDED RNA VECTOR FOR SYSTEMIC CANCER TREATMENT LEVITZKI ALEXANDER (IL) 2016-08-10 EP disclosed
US-9006406-B2 EGFR-homing double-stranded RNA vector for systemic cancer treatment Levitzki, Alexander (IL) 2015-04-14 US disclosed
US-20120021006-A1 EGFR-HOMING DOUBLE-STRANDED RNA VECTOR FOR SYSTEMIC CANCER TREATMENT TARGIMMUNE THERAPEUTICS AG (CH) 2012-01-26 US disclosed